ORCHID ORTHOPEDIC SOLUTIONS SHEFFIELD LTD

Company number

01090667

Status

Active

Incorporation

1973-01-12

Last accounts made up

2024-12-31

Account category

FULL

Primary SIC

32500

Hubs

UK Healthcare

Accounting basis

IFRS

Reporting scope

Standalone (parent only)

Auditor

Ernst & Young LLP

Audit opinion

Unqualified (clean)

Going concern

Material uncertainty disclosed

“The financial statements have been prepared on a going concern basis. As at 31 December 2024, the Company had net assets of £16,164k (2023: net assets of £12,185k) and net current liabilities of £21,243k (2023: net current liabilities of £16,905k). At the balance sheet date, the company owed monies to fellow group companies of £37,383k. In response to the net current liabilities position and intercompany borrowings position, when performing their going concern assessment, which covers the period through to 31 March 2027, the directors have obtained a parental support letter from Femur Buyer Inc ("US Group") to support their going concern conclusions. The parent company, Femur Buyer Inc, has confirmed that it will provide financial support to the Company to enable it to meet its liabilities as they fall due throughout the going concern assessment period. The Directors have considered the ability of the parent company to provide that support required. This included an assessment of the Group's liquidity, debt position and future plans. In October 2025, Femur Buyer Inc restructured its outstanding debt, strengthening the Company's liquidity and overall financial position through to 31 March 2027. In addition, the directors of Femur Buyer Inc have signed a merger deal with Tecomet on 14 January 2026, to improve cost synergies in the long term, subject to Regulatory approval and closing conditions. The merger will not be final until no earlier than Q2 2026 and both companies will continue to operate separately until Regulatory approval is complete. As part of this specific deal, a debt restructure will be required, which would require a portion of Femur Buyer Inc's current debt to be either forgiven or capitalized so that the new group has sufficient facilities available in the foreseeable future. However, as at this time, there is no certainty as to whether the specific merger deal will receive Regulatory approval. There is also no certainty to the future intentions of the enlarged Group in respect of this Company, should the deal complete. Given this, the Directors have concluded that two material uncertainties exist in respect of the FY2024 financial statements with these being: * whether the proposed M&A deal will actually be completed; and, * if the M&A deal concludes, there is no certainty as to the future funding structures and ability of the enlarged Group to service the debt, and there is no certainty as to the future intentions of the enlarged Group in respect of this Company. These circumstances indicate the existence of material uncertainties related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern and, therefore, that it may be unable to realize its assets and discharge its liabilities in the normal course of business. The Company's financial statements do not include the adjustments that would result if the Company were unable to operate as a going concern.”

Significant events

• “In late October 2025, Femur Buyer, Inc. group (the "Group") restructured its outstanding debt, strengthening Femur Buyer Inc Groups' liquidity. As part of this transaction, all of its outstanding second lien debt was exchanged for common equity and a portion of its first lien debt was exchanged for preferred equity. In addition, the directors of Femur Buyer Inc have signed a merger deal with Tecomet on 14 January 2026, to improve cost synergies in the long term, subject to Regulatory approval and closing conditions. The merger will not be final until no earlier than Q2 2026 and both companies will continue to operate separately until Regulatory approval is complete.”

Auditor / going-concern / subsidiary information is extracted from the PDF version of the latest annual accounts and is not tagged in iXBRL. About these numbers